Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Magrolimab (magrolimab)
• Obinutuzumab (Gazyva) (obinutuzumab)
• Venetoclax (Venclyxto) (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2025-02-04